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 Peripheral neuropathy is a common side effect of platinum-based chemotherapeutic 
compounds such as oxaliplatin and cisplatin, taxanes such as paclitaxel and vinca 
alkaloids such as vincristine. Among them, oxaliplatin, a third-generation, 
platinum-based chemotherapeutic agent, has superior activity as a first-line treatment in 
advanced colorectal cancer and as adjuvant treatment. Oxaliplatin has a better safety 
profile, characterized by lower hematotoxicity and manageable gastrointestinal toxicity, 
than other platinum-based chemotherapeutics. However, oxaliplatin induces moderate 
to severe peripheral neuropathy, characterized by acute and chronic, two types of 
neurological symptoms. The acute neuropathy is specific to oxaliplatin and is 
exacerbated by cold. While the oxaliplatin-induced chronic peripheral neuropathy can 
be explained, at least in part, by the accumulation of platinum adducts in the dorsal root 
ganglia (DRG), the mechanisms underlying the acute peripheral neuropathy are poorly 
understood. 
 On the other hand, transient receptor potential (TRP) channels are a family of 
nonselective cation channels. Some TRP channels are expressed in sensory neurons, 
including TRPV1, TRPA1, and TRPM8. These receptors are thermosensitive and play a 
critical role in pain generation. The TRP ankyrin 1 (TRPA1), a calcium-permeable 
cation channel co-expressed with TRPV1 in a subpopulation of nociceptive primary 
sensory neurons is activated by pungent ingredients present in an array of spices, 
including allyl isothiocyanate (mustard, wasabi), cinnamaldehyde (cinnamon), and 
others. It has been reported that TRPA1 is activated by noxious cold temperature and 
robust evidence has been accumulated indicating that reactive oxygen species (ROS) 
and various endogenous byproducts deriving from ROS induced peroxidation of plasma 
membrane phospholipids gate TRPA1, thereby causing pain and neurogenic 
inflammation. TRPA1 is a sensor of both cold temperature and oxidative stress. 
Therefore, I have hypothesized that TRPA1 mediate cold hypersensitivity provoked by 
oxaliplatin. The present data show that: 
 In chapter 1, I established a new oxaliplatin-induced acute cold hypersensitivity 
mouse model. A single intraperitoneal administration of oxaliplatin induced a 
characteristic acute cold hypersensitivity, while mechanical hypersensitivity was not 
observed, which is similar with the clinical observation. Then the effects of standard 
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analgesics on the oxaliplatin-induced cold hypersensitivity were evaluated in this mouse 
model. I found that gabapentin, mexiletine, tramadol and calcium gluconate 
significantly inhibited, and morphine and milnacipran decreased the acute cold 
hypersensitivity, while diclofenac and amitriptyline had no effects. These results 
suggest that gabapentin, mexiletine and calcium gluconate are effective against 
oxaliplatin-induced acute peripheral neuropathy. 
 In chapter 2, the involvements of thermosensitive TRP channels were evaluated. 
Pre-treatment of oxalipaltin enhanced TRPA1 channel agonist-evoked nocifensive 
behaviors and [Ca2+]i responses in cultured DRG neurons, respectively. Moreover, the 
oxaliplatin-induced cold hypersensitivity was inhibited by a TRPA1 antagonist, 
HC030031 and TRPA1 knockout mice. The present data suggest that the acute cold 
hypersensitivity characteristically induced by oxaliplatin could be linked to an enhanced 
responsiveness of TRPA1, but not TRPM8 and TRPV1, on DRG neurons.  
 In chapter 3, the mechanisms of TRPA1 activation/sensitization were further 
investigated. High concentration of oxaliplatin elicited TRPA1 activation directly, while 
low concentration of oxaliplatin pretreatment enhanced hydrogen peroxide 
(H2O2)-evoked TRPA1 responses. These results suggest oxaliplatin could sensitize 
TRPA1 function, and subsequently the sensitized TRPA1 is activated by ROS probably 
produced from oxaliplatin-mediated mitochondrial dysfunction, which may contribute 
to the oxaliplatin-induced acute peripheral neuropathy.  










2-APB 2-Aminoethoxydiphenyl borate 
AITC allyl isothiocyanate 
ANOVA analysis of variance 
DMEM Dulbecco's modified Eagle medium 
DMSO dimethyl sulfoxide 
DRG  dorsal root ganglia 
EDTA ethylenediaminetetraacetic acid 
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GSH glutathione 
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PHD Prolyl hydroxylases 
ROS reactive oxygen species 
SNRI selective serotonin noradrenaline reuptake inhibitor 
TRP transient receptor potential 
TRPA1 transient receptor potential ankyrin 1 
TRPM8 transient receptor potential melastatin 8 
TRPV1 transient receptor potential vanilloid 1 










Chapter 1 Establishment of oxaliplatin-induced acute 
peripheral neuropathy in mice 
Oxaliplatin, a third-generation, platinum-based chemotherapeutic agent, is a 
component of the FOLFOX regimen (oxaliplatin + 5-fluorouracil + leucovorin) as a 
standard adjuvant treatment for advanced colorectal cancer [1, 2]. Oxaliplatin has a 
better safety profile, characterized by lower hematotoxicity and manageable 
gastrointestinal toxicity, than other platinum-based chemotherapeutics. However, 
peripheral neuropathy is a common side effect of platinum-based chemotherapeutic 
compounds such as oxaliplatin and cisplatin, taxanes such as paclitaxel and vinca 
alkaloids such as vincristine [3]. Oxaliplatin induces moderate to severe peripheral 
neuropathy, characterized by two types of neurological symptoms [4, 5]. During or 
within hours after its infusion, an acute neuropathy, including acral numbness, 
paresthesia, dysesthesia and pain, develops in almost all patients that intensify over time, 
causing serious discomfort. After multiple chemotherapy cycles, chronic cumulative 
peripheral neuropathy, such as sensory loss and motor dysfunction, occurs in 10-15% of 
treated patients, a rate similar to that of cisplatin [5, 6]. The acute neuropathy is specific 
to oxaliplatin [4, 5, 7], while effective pharmacological strategy for the management of 
oxaliplatin-induced acute peripheral neuropathy remains controversial [8-10]. 
Many studies in animal models focus on the oxaliplatin-induced chronic and/or 
subacute painful peripheral neuropathy that appear several days to several weeks after 
oxaliplatin administration [11-13]. However, oxaliplatin-induced acute peripheral 
neuropathy is poorly characterized in animal models. In chapter 1, I tried to produce a 
new mouse model which could represent the acute neuropathy characteristic to 
oxaliplatin and assessed the effects of standard analgesics, such as the non-steroidal 
anti-inflammatory agent (NSAID), opioid analgesics, tricyclic antidepressant, serotonin 
and noradrenaline reuptake inhibitor (SNRI), calcium channel α2-δ ligand, local 
anesthetic and calcium gluconate [8-10], on the oxaliplatin-induced acute cold 





 The male C57BL/6 J mice aged between 6-8 week-old were purchased from Japan 
SLC (Shizuoka, Japan). All mice were housed under constant ambient temperature 
(24 ± 1°C) and humidity (55 ± 10%), with alternate light-dark cycles from 8:00 a.m. to 
20:00 p.m.. Food and water were freely available. All experiments were conducted in 
accordance with the Ethical Guidelines of the Kyoto University Animal 
Experimentation Committee.  
Drugs 
 Oxaliplatin and sodium oxalate were purchased from Wako Pure Chemical Industries, 
Ltd. (Osaka, Japan) and freshly dissolved in 5% glucose solution. 
cis-Diammineplatinum(II) dichloride (cisplatin) and paclitaxel were purchased from 
Sigma-Aldrich, Inc. (St. Louis, MO, USA). Cisplatin was freshly dissolved in sterile 
saline, and paclitaxel in Cremophor® EL (Sigma-Aldrich) and dehydrated ethanol (1:1) 
to obtain a stock solution. Prior to its administration, paclitaxel was further diluted with 
sterile saline. Mice received a single intraperitoneal (i.p.) administration of oxaliplatin 
(1, 5 or 10 mg/kg), cisplatin (5 mg/kg), paclitaxel (6 mg/kg), or vehicle. The doses of 
these chemotherapeutic agents were chosen based on previous reports with a single 
intraperitoneal administration [11, 13-17].  
  Morphine hydrochloride (Takeda Pharmaceutical Co., Osaka), tramadol 
hydrochloride (gift from Nippon Shinyaku, Kyoto), amitriptyline hydrochloride (LKT 
Laboratories, MN, USA), milnacipran hydrochloride (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), diclofenac sodium salt, gabapentin and mexiletine hydrochloride 
(Sigma-Aldrich, St. Louis, MO, USA) were freshly dissolved in sterile saline. Morphine 
and tramadol were administrated subcutaneously (s.c.), and milnacipran and mexiletine 
were administrated intraperitoneally 30 minutes before, and diclofenac, gabapentin and 
amitriptyline were administered intraperitoneally 1 hour before the behavioral test at a 
volume of 10 ml/kg. Calcium gluconate monohydrate (Wako) was freshly dissolved in 
5% glucose solution, and was infused intravenously (i.v.) just before oxaliplatin 




von Frey filament test 
 Mechanical sensitivity was assessed by the up-down method using calibrated von 
Frey filaments, as previously described with slight modifications [18, 19]. Mice were 
acclimated on a wire-mesh floor in Plexiglas cubicles (9 cm L × 5 cm W × 5 cm H) 
for 1 h, after which mechanical sensitivity was evaluated using a set of four calibrated 
von Frey fibers (0.07, 0.16, 0.4, 1.0 g; Stoelting Co., Wood Dale, IL USA) applied to 
the plantar surface of the left hindpaw for a few seconds until they bent slightly. A 
withdrawal reflex of the hindpaw during stimulation or immediately after stimulus 
removal was considered a positive response. If a positive response was obtained to the 
first stimulus, the 0.16-g filament, then the next lower filament was applied; if there was 
no response, the next higher filament was used. After the first change in responses, the 
experiment was continued until four additional responses were obtained. The 50% paw 
withdrawal threshold value was then calculated [19].  
Cold-plate test 
 Cold sensitivity was assessed with the Hot/Cold Plate (Ugo Basile, Milan, Italy). 
Mice were allowed to acclimate to the testing apparatus for 1 h, after which they were 
individually placed on the center of a cold plate maintained at 5°C in a transparent 
Plexiglas cylinder. Escape behaviors were observed for 60 s and graded with a score of 
0 = no response; 1 = moderate effort to avoid cold, such as lifting a hindpaw or 
walking backwards; and 2 = vigorous effort to escape cold, such as jumping. The sum 
of the scores recorded within a 60-s period was calculated.  
Statistical analysis 
 The data were analyzed using Graphpad Prism and are presented as means ± S.E.M. 
Statistical significance was calculated by one-way or two-way analyses of variance 
(ANOVA), followed by the Bonferroni or Tukey-Kramer post-hoc test. Time-course 
data were analyzed by two-way ANOVA for repeated measures, followed by the 
Bonferroni post-hoc test. In all cases, differences of p < 0.05 were considered 




Effect of oxaliplatin, cisplatin, and paclitaxel on acute mechanical and 
cold sensitivities 
 The effects of a single administration of oxaliplatin on behavioral sensitivity to 
mechanical and cold stimuli were assessed in a von Frey filament test and a cold plate 
test, respectively (Fig. 1-1). A single intraperitoneal administration of oxaliplatin 
(5 mg/kg) significantly decreased the 50% withdrawal threshold to mechanical 
stimulation with von Frey filaments (F1, 14 = 16.85, p < 0.01). While a decrease in the 
mechanical threshold was not apparent 2 h after oxaliplatin administration, the response 
became significant at 1 day and lasted for at least 7 days, compared with the 
vehicle-administered group (Fig. 1-1A). In the cold plate test, oxaliplatin (5 mg/kg) 
significantly increased the escape behavior scores measured in response to cold 
stimulation (F1,10 = 10.06, p < 0.01). Significant increases in the cold escape behaviors 
were observed after 2 h and lasted for at least 7 days after oxaliplatin administration, 
compared with the vehicle-administered group (Fig. 1-1B). I assessed the 
dose-dependent effect of oxaliplatin on the acute cold hypersensitivity in the cold plate 
test. The cold escape behavior scores were significantly increased 2 h after the 
administration of oxaliplatin (1, 5 and 10 mg/kg) in a dose-dependent manner 
(F3,20 = 18.57, p < 0.001), and the significant effects were observed at doses of 5 and 
10 mg/kg, but not 1 mg/kg, compared with the vehicle-administered group (Fig. 1-1C). 
Oxaliplatin is metabolized to oxalate and dichloro(1,2-diaminocyclohexane)platinum. 
As oxaliplatin-induced cold hypersensitivity measured in the acetone test is caused, at 
least in part, by oxalate [13], I examined the effect of oxalate on the cold sensitivity in 
the cold plate test. The dose of sodium oxalate (1.7 mg/kg) was calculated from the 
molecular weight of oxaliplatin included in the oxaliplatin preparation (5 mg/kg). A 
single intraperitoneal administration of oxalate significantly increased the cold escape 
behavior scores (F1,12 = 14.81, p < 0.01). Significant increases were observed after 2 h 
and lasted for 3 days after oxaliplatin administration, compared with the 
vehicle-administered group (Fig. 1-1D).  
 The repeated administration of cisplatin or paclitaxel is reported to produce 
mechanical and thermal hypersensitivity, with maximal effects observed several days to 
several weeks after drug administration [15, 20-22]. In this study, I asked whether 
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cisplatin and paclitaxel induce an early-phase acute mechanical or cold hypersensitivity. 
However, 2 h after a single intraperitoneal administration of cisplatin (5 mg/kg) or 
paclitaxel (6 mg/kg) there was no change in the 50% withdrawal threshold to 
mechanical stimulation) or in the escape behavior scores measured in response to cold 
stimulation (Fig. 1-2). 
 
Figure 1-1. A single administration of oxaliplatin induces acute cold hypersensitivity, but not 
acute mechanical hypersensitivity. (A, B) Mice were intraperitoneally administered either vehicle or 
oxaliplatin (5 mg/kg). At the indicated times, the 50% withdrawal threshold to mechanical stimulation 
and escape behaviors in response to cold stimulation (5°C) were evaluated in a von Frey filament test 
(A, n = 8) and a cold plate test (B, n = 6), respectively. Cold escape behaviors were scored depending 
on a behavioral assessment, with the total score calculated for a period of 60 s. * p < 0.05, ** p < 0.01 
compared with vehicle-administered group. (C) Mice were intraperitoneally administered vehicle or 
oxaliplatin (1, 5 or 10 mg/kg). Two hours after the administration, the cold escape behaviors were 
scored in the cold plate test. n = 6. ** p < 0.01, *** p < 0.001 compared with vehicle-administered 
group. (D) Mice were intraperitoneally administered either vehicle or oxalate (1.7 mg/kg). At the 
indicated times, the cold escape behaviors were scored in the cold plate test. n = 7. * p < 0.05, ** 
p < 0.01 compared with vehicle-administered group. Data are presented as the means ± S.E.M. 
Statistical significance was calculated by one-way ANOVA (C) or two-way repeated measures ANOVA, 
followed by Bonferroni post-hoc test. 
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Effects of analgesics on oxaliplatin-induced acute cold hypersensitivity 
 An NSAID, diclofenac (25 and 50 mg/kg) had no effect on the oxaliplatin-induced 
acute cold hypersensitivity (Fig. 1-3A). A strong opioid analgesic, morphine (5 and 10 
mg/kg) tended to inhibit the cold hypersensitivity, although there was no significant 
difference when compared with vehicle-administered group (Fig. 1-3B). Tramadol (10 
and 20 mg/kg) dose-dependently decreased the cold hypersensitivity. A significant 
difference was observed at 20 mg/kg when compared with vehicle-administered group 
(Fig. 1-3C). A calcium channel α2-δ ligand, gabapentin (10 and 30 mg/kg) 
dose-dependently decreased the cold hypersensitivity. A significant difference was 
observed at 30 mg/kg when compared with vehicle-administered group (Fig. 1-3D). A 
tricyclic antidepressant, amitriptyline (5 and 10 mg/kg) had no effect on the cold 
hypersensitivity (Fig. 1-3E). An SNRI, milnacipran (10 and 30 mg/kg) tended to inhibit 
the cold hypersensitivity, although there was no significant difference when compared 
with vehicle-administered group (Fig. 1-3F). An orally available local anesthetic, 
mexiletine (10 and 30 mg/kg) dose-dependently decreased the cold hypersensitivity. A 
significant difference was observed at 30 mg/kg when compared with 
vehicle-administered group (Fig. 1-3G). Calcium gluconate (0.5 mmol/kg) infused 
before oxaliplatin administration significantly inhibited acute cold hypersensitivity, 
compared with vehicle-infused group (Fig. 1-3H).  
Figure 1-2. Neither cisplatin 
nor paclitaxel induces acute 
mechanical and cold 
hypersensitivity. Mice were 
intraperitoneally administered 
vehicle, cisplatin (5 mg/kg; A, 
B), or paclitaxel (6 mg/kg; C, 
D), and 2 h later the 50% 
withdrawal threshold to 
mechanical stimulation (A, C) 
and the escape behaviors in 
response to cold stimulation 
(B, D) were evaluated. Data 
are presented as the 





Figure 1-3. Effects of analgesics on oxaliplatin-induced acute cold hypersensitivity. Mice were 
given intraperitoneal administration of oxaliplatin (5 mg/kg). Cold plate tests were performed 2 hours 
after oxaliplatin administration. Morphine (5 and 10 mg/kg, n = 6-8), tramadol (10 and 20 mg/kg, n = 
5-8), milnacipran (10 and 30 mg/kg, n = 4-8) and mexiletine (10 and 30 mg/kg, n = 5-8) were 
administered intraperitoneally 30 minutes before the tests. Diclofenac (25 and 50 mg/kg, n = 5-9), 
gabapentin (10 and 30 mg/kg, n = 4-9) and amitriptyline (5 and 10 mg/kg, n = 5-9) were administered 
intraperitoneally 60 minutes before the tests. Calcium gluconate (0.5 mmol/kg) was administered 
intravenously before oxaliplatin administration (n = 3-4). Data are presented as the means ± S.E.M. * p 
< 0.05, ** p < 0.01, *** p < 0.001 compared to the group treated with vehicle alone instead of oxaliplatin. 




 The peripheral neuropathy caused by chemotherapeutic agents, including oxaliplatin, 
has been widely evaluated experimentally in rodents as hypersensitivity to mechanical 
and thermal stimuli in terms of mechanical allodynia and thermal hyperalgesia, 
respectively. Previous studies in animal models largely focus on the oxaliplatin-induced 
chronic painful neuropathy that appears several days to several weeks after oxaliplatin 
administration [11, 14, 23-25], while oxaliplatin-induced acute neuropathy is less well 
characterized [13]. My findings in mice, in which cold hypersensitivity was detected as 
early as 2 h after oxaliplatin administration, is consistent with the clinical observation 
of a characteristic acute sensory neuropathy triggered by cold that appears during or 
within hours of oxaliplatin infusion. By contrast, mechanical hypersensitivity in mice 
was observed 1 day, but not as early as 2 h, after drug administration and persisted for 
at least 7 days, consistent with previous reports [11, 13, 23]. Moreover, the rapid-onset 
cold hypersensitivity was not produced by another platinum-based chemotherapeutic 
agent, cisplatin, or by the non-platinum-containing chemotherapeutic agent, paclitaxel, 
both of which are known to induce chronic peripheral neuropathy following repeated 
administration [15, 20-22]. These findings suggest that the rapid-onset cold 
hypersensitivity is representative of the acute peripheral sensory neuropathy 
characteristic to oxaliplatin in mice and that the mouse model is suitable for exploring 
the mechanisms of this side effect and assessing effects of therapeutic drugs. 
 NSAIDs are representative broad-spectrum analgesics especially for nociceptive pain, 
while they are ineffective on neuropathic pain. Although NSAIDs are initially treated 
for the management of chemotherapy-induced painful peripheral neuropathy [8], it 
remains unclear whether acute peripheral neuropathy induced by oxaliplatin involves 
inflammatory components. The present results suggest that NSAIDs are ineffective on 
oxaliplatin-induced acute peripheral neuropathy. 
 It is reported that morphine (1-4 mg/kg) dose-dependently inhibits the chronic and 
subacute cold allodynia induced by oxaliplatin in rats [11, 12]. However, the present 
results suggest that morphine is less efficacious against oxaliplatin-induced acute 
peripheral neuropathy. 
 Tramadol exhibits analgesic effect through both µ-opioid receptor agonistic activity 
and antidepressant-like enhancement of descending serotoninergic and noradrenergic 
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pain inhibitory systems by blocking monoamine reuptake. The dual analgesic 
mechanisms are likely to contribute to its efficacy against neuropathic pain [26]. Indeed, 
it is clinically reported that tramadol/acetaminophen combination is effective in the 
management of oxaliplatin-induced painful neuropathy [27]. The present results further 
suggest that tramadol alleviates oxaliplatin-induced acute peripheral neuropathy 
probably due to its complementary and synergistic actions. 
 Gabapentin is often used as a first-choice drug for the management of neuropathic 
pain, as well as pregabalin [28]. However, gabapentin has not well proven efficacy in 
the treatment of oxaliplatin-induced peripheral neuropathy. Some clinical studies have 
not confirmed the ameliorating effect of gabapentin, while pregabalin reduced the 
severity of peripheral neuropathy in patients treated with oxaliplatin [9]. In animal 
models, gabapentin reduces oxaliplatin-induced chronic and/or subacute peripheral 
neuropathy [13, 29]. Furthermore, mRNA expression of Ca2+ channel α2δ-1 subunit in 
the dorsal root ganglia is increased 10 days after oxaliplatin administration [29]. My 
present results suggest that gabapentin alleviates oxaliplatin-induced acute peripheral 
neuropathy.  
 Tricyclic antidepressants and SNRIs are widely used as first-choice drugs for the 
management of neuropathic pain [28]. Both antidepressants inhibit neuropathic pain by 
blocking noradrenaline and serotonin reuptake. However, their efficacy on the 
oxaliplatin-induced peripheral neuropathy is controversial [9]. In animal models, 
repeated administration of amitriptyline reduces oxaliplatin-induced chronic mechanical 
allodynia [30]. It is considered that disinhibition and imbalance of the descending 
serotonergic and noradrenergic pain inhibitory pathways contribute to neuropathic pain. 
However, oxaliplatin-induced acute peripheral neuropathy is unlikely to be mediated 
through the disinhibition and imbalance of these pathways, which may result in no and 
weak efficacy of these antidepressants. On the other hand, anti-allodynic effect of 
milnacipran is more potent than amitriptyline on cold allodynia in a neuropathic pain 
model rats [31], consistent with the present results. 
 Mexiletine blocks voltage-gated Na+ channels, and is clinically used for painful 
diabetic neuropathy. An aspect of the oxaliplatin-induced peripheral neuropathy is 
mediated through voltage-gated Na+ channels in sensory neurons [32]. In animal models, 
mexiletine dose-dependently inhibits the oxaliplatin-induced chronic cold allodynia [33]. 
Taken together, mexiletine is a potential treatment option for the oxaliplatin-induced 
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acute neuropathy. 
 Infusion of calcium and magnesium has been clinically treated for prevention and 
management of oxaliplatin-induced peripheral neuropathy, although a recent 
meta-analysis does not support them [10]. In animal models, pre-administration of 
calcium reduces the oxaliplatin-induced chronic and/or subacute cold hyperalgesia but 
not mechanical allodynia [13]. It is hypothesized that chelation of calcium by an 
oxaliplatin metabolite, oxalate, induces functional impairment of voltage-gated Na+ 
channels, resulting in hyperexcitability of sensory neurons. Therefore, calcium infusion 
could enhance the closing rate of Na+ channels, which may decrease the neuronal 
hyperexcitability induced by oxaliplatin [32]. The present results suggest that 
pre-infusion of calcium before oxaliplatin could prevent, at least, the 
oxaliplatin-induced acute peripheral neuropathy. 
 In conclusion, the present study suggests that the rapid-onset cold hypersensitivity is 
representative of the acute peripheral sensory neuropathy characteristic to oxaliplatin in 
mice. The data also provide evidences the efficacy of tramadol, Ca2+ channel α2-δ 
ligands, Na+ channel blockers and calcium gluconate, rather than opioid analgesics, 





Chapter 2 Involvement of thermal TRP channels in 
oxaliplatin-induced acute cold hypersensitivity 
 Oxaliplatin, widely used to treat advanced metastatic colorectal cancer, induces 
moderate to severe peripheral neuropathy, characterized by acute and chronic, two types 
of neurological symptoms [4, 5]. During or within hours after its infusion, an acute 
neuropathy, including acral numbness, paresthesia, dysesthesia and pain, develops in 
almost all patients that intensify over time, causing serious discomfort. While the 
oxaliplatin-induced chronic peripheral neuropathy can be explained, at least in part, by 
the accumulation of platinum adducts in the dorsal root ganglia (DRG) [34], the 
mechanisms underlying the acute peripheral neuropathy are poorly understood. 
 On the other hand, sensory neurons express several types of transient receptor 
potential (TRP) channels, including TRPV1, TRPA1, and TRPM8. These receptors are 
thermosensitive and play a critical role in pain generation [35, 36]. TRPV1 is activated 
by noxious heat, acidity, and noxious chemical stimuli such as capsaicin [37, 38]. 
TRPA1 is activated by noxious cold and a large number of irritants including 
allyl-isothiocyanate (AITC), cinnamaldehyde, allicin, and aldehydes, as well as oxygen, 
reactive-oxygen and nitrogen species [39-43]. TRPM8 is activated by innocuous as well 
as noxious cold, and by menthol, the ingredient of peppermint that produces its cooling 
sensation [44, 45]. Although still a matter of debate, recent evidence suggests that these 
thermosensitive TRP channels are responsible for chemotherapy-induced peripheral 
neuropathies. In rodents, oxaliplatin increases the expression of TRPA1 [14, 23, 24] and 
TRPM8 [25], but see [14, 24], but not TRPV1 [24], mRNAs in sensory ganglia. In 
mouse trigeminal ganglia, cisplatin increases TRPV1 and TRPA1 mRNAs levels [24], 
but see [46]. Oxaliplatin-induced mechanical and cold hypersensitivity is abolished by 
pharmacological inhibition or a gene-deficiency of TRPA1 [14, 23], TRPV1 [24], or 
TRPM8 [14, 25], but see [46], while cisplatin- and paclitaxel-induced painful 
neuropathy being inhibited by an antagonist or genetic deficiency of TRPV1 [20, 21, 
24]. In those studies, chemotherapy-induced hypersensitivity was assessed several days 
to several weeks after a single or repeated administration of the compounds, which may 
reflect the subacute or chronic phase of chemotherapy-induced peripheral neuropathy.  
 In chapter 2, I investigated whether TRPA1, TRPM8, and TRPV1 are involved in the 




 The male C57BL/6 J mice aged between 6-8 week-old were purchased from Japan 
SLC (Shizuoka, Japan). For experiments investigating the effects of TRPA1 deficiency, 
wild-type (Trpa1+/+) and homozygous (Trpa1−/−) mouse littermates from 
heterozygous/heterozygous Trpa1+/− mice were used (6- to 8-weeks-old). Trpa1−/− mice 
bred from heterozygous mice with a C57BL/6 × 129 S1 background were obtained 
from Jackson Laboratory (Bar Harbor, ME) and genotyped as previously described [47]. 
The Trpa1−/− mouse line was backcrossed to C57BL/6 J mice for at least 10 generations. 
All mice were housed under constant ambient temperature (24 ± 1°C) and humidity 
(55 ± 10%), with alternate light-dark cycles from 8:00 a.m. to 20:00 p.m.. Food and 
water were freely available. All experiments were conducted in accordance with the 
Ethical Guidelines of the Kyoto University Animal Experimentation Committee.  
Drugs 
 Oxaliplatin and sodium oxalate were purchased from Wako Pure Chemical Industries, 
Ltd. (Osaka, Japan) and freshly dissolved in 5% glucose solution. 
cis-Diammineplatinum(II) dichloride (cisplatin) and paclitaxel were purchased from 
Sigma-Aldrich, Inc. (St. Louis, MO, USA). Cisplatin was freshly dissolved in sterile 
saline, and paclitaxel in Cremophor® EL (Sigma-Aldrich) and dehydrated ethanol (1:1) 
to obtain a stock solution. Prior to its administration, paclitaxel was further diluted with 
sterile saline. Mice received a single intraperitoneal administration of oxaliplatin (1, 5 
or 10 mg/kg), cisplatin (5 mg/kg), paclitaxel (6 mg/kg), or vehicle. The doses of these 
chemotherapeutic agents were chosen based on previous reports with a single 
intraperitoneal administration [11, 13-17]. HC-030031 (100 mg/kg, Enzo Life Sciences, 




Cold plate test 
 Cold sensitivity was assessed with the hot/cold plate (Ugo Basile, Milan, Italy). Mice 
were allowed to acclimate to the testing apparatus for 1 h, after which they were 
individually placed on the center of a cold plate maintained at 5°C in a transparent 
Plexiglas cylinder. Escape behaviors were observed for 60 s and graded with a score of 
0 = no response; 1 = moderate effort to avoid cold, such as lifting a hindpaw or 
walking backwards; and 2 = vigorous effort to escape cold, such as jumping. The sum 
of the scores recorded within a 60-s period was calculated.  
TRP channel agonist-evoked nocifensive behaviors 
 DL-Menthol (Sigma-Aldrich) and capsaicin (Nacalai Tesque, Kyoto, Japan) were 
dissolved in dimethyl sulfoxide (DMSO) as a stock solution (800 mg/ml and 80 mg/ml, 
respectively). Allyl-isothiocyanate (AITC, Wako), menthol, and capsaicin were diluted 
in corn oil (Sigma-Aldrich). The mice were allowed to acclimate in a clear acrylic 
cylinder for at least 40 min after which 20 µl of AITC (0.1%), capsaicin (1.6 µg) or 
menthol (160 µg) was subcutaneously injected into the plantar surface of the left 
hindpaw. AITC- and capsaicin-evoked nocifensive behaviors were measured as the 
durations of consecutive licking and flicking behaviors for 20 min and 5 min, 
respectively. Menthol-evoked nocifensive-like behaviors (i.e., hindpaw lifting and 
backwards walking) were scored as for the cold plate test described above. The sum of 
the scores recorded within a 5-min observation period was calculated.  
Primary cultures of DRG neurons 
 Bilateral L1-L6 DRGs were harvested from two freshly killed adult male C57BL/6 J 
mice. DRGs were incubated for 1 h at 37°C in Hank's balanced salt solution (137 mM 
NaCl, 5.4 mM KCl, 0.34 mM Na2HPO4, 0.44 mM KH2PO4, 5.6 mM D-glucose, 
2.4 mM HEPES, 25 mM glucose, pH 7.4) containing 0.3% collagenase and 0.4% 
dispase. A Percoll (Sigma-Aldrich) gradient was used to separate myelin and nerve 
debris from DRG neurons as follows: Solutions of 30% and 60% Percoll were prepared 
with L15 medium. The 30% Percoll was gently layered over the 60% Percoll solution, 
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and the cell suspension over the Percoll gradient. After 10 min of centrifugation at 
1800 × g, the cells were harvested from the Percoll interface and suspended in 
8 ml L15 medium, then centrifuged again for 5 min at 1800 × g. The supernatant was 
removed and the cell pellet resuspended in 70 µl Dulbecco's modified Eagle medium 
(DMEM), containing 10% heat-inactivated fetal bovine serum, penicillin G (100 U/ml), 
and streptomycin (100 µg/ml), followed by plating onto laminin-coated coverslips 
(3 mm × 7 mm) and incubation at 37°C. After 4 h incubation, 1.5 ml DMEM was 
added and the cells were incubated again, this time overnight at 37°C.  
Fluorometric Ca2+ imaging  
 Cultured DRG neurons on coverslips were loaded for 30 min with 5 µM fura-2/AM 
(Dojindo, Kumamoto, Japan) in Krebs-Ringer solution (140 mM NaCl, 5 mM KCl, 
1 mM MgCl2, 2 mM CaCl2, 10 mM glucose, 10 mM HEPES) containing 0.01% 
cremophore EL (Sigma-Aldrich). The cells were then washed with Krebs-Ringer 
solution and transferred to an imaging chamber. The AQUACOSMOS/ORCA-AG 
imaging system (Hamamatsu Photonics, Shizuoka, Japan) was used to capture the 
fluorescence images obtained with alternating excitation at 340 and 380 nm and 
emission at > 510 nm. Emission ratios (F340/F380) were calculated for each 5-s interval 
after subtraction of the background. The cells showing the F340/F380 ratio of over 1.4 at 
the baseline were excluded. A cellular response to a drug was defined as an increase in 
the F340/F380 ratio by more than 0.2 during the 3-min application period. All experiments 
were performed at room temperature. Oxaliplatin stock solution (5 mM) was prepared 
in sterile water and further diluted in DMEM to 100 µM before every experiment. 
AITC (100 mM), menthol (1 M), and capsaicin (100 mM) were prepared as stock 
solutions in DMSO and diluted in Krebs-Ringer solution.  
Statistical analysis 
 The data were analyzed using Graphpad Prism and are presented as means ± S.E.M. 
Statistical significance was calculated by one-way or two-way analyses of variance 
(ANOVA), followed by the Bonferroni post-hoc test. In all cases, differences of 




Effects of oxaliplatin, cisplatin, and paclitaxel on AITC-, menthol- and 
capsaicin-evoked nocifensive behaviors 
 To investigate the involvement of thermosensitive TRP channels, I assessed the effects 
of oxaliplatin, cisplatin, and paclitaxel on the nocifensive behaviors evoked by TRP 
channel agonists. Intraplantar (i.pl.) injection of AITC (0.1%, 20 µl), a TRPA1 agonist, 
evoked nocifensive behaviors such as licking and flicking of the injected hindpaw, 
whereas this was not the case following i.pl. vehicle injection. When mice were 
preinjected with oxaliplatin (1, 5 and 10 mg/kg, i.p.) and then tested 2 h later, the 
duration of the AITC-evoked nocifensive behaviors were significantly enhanced in a 
dose-dependent manner (F3,31 = 5.711, p < 0.001). The significant differences were 
observed at doses of 5 and 10 mg/kg, but not 1 mg/kg, compared with mice preinjected 
with vehicle (Fig. 2-1A). I examined the time course of the oxaliplatin-induced 
enhancement of the AITC-evoked nocifensive behaviors. The duration of the 
AITC-evoked nocifensive behaviors were significantly enhanced even 1 and 3 days, but 
not 7 days after a single administration of oxaliplatin (5 mg/kg, i.p.), compared with 
mice preinjected with vehicle (Fig. 2-1B). Intraplantar injection of menthol (160 µg), a 
TRPM8/TRPA1 agonist [48], evoked nocifensive-like behaviors, such as backwards 
walking and lifting of the injected hindpaw. In mice preinjected with oxaliplatin 2 h 
prior to testing, the scores of menthol-evoked nocifensive-like behaviors were 
significantly higher than those of vehicle-administered mice (Fig. 2-1C). The 
enhancement of menthol-evoked nocifensive-like behaviors induced by oxaliplatin 
pretreatment was significantly inhibited in Trpa1−/− mice to the scores in 
vehicle-pretreated mice (Fig. 2-1D). Intraplantar injection of the TRPV1 agonist 
capsaicin (1.6 µg) evoked nocifensive behaviors such as licking and flicking of the 
injected hindpaw. There was no significant difference in the duration of the 
capsaicin-evoked nocifensive behaviors between vehicle- and oxaliplatin-preinjected 
mice (Fig. 2-1E).  
When mice were preinjected with oxalate (1.7 mg/kg, i.p.) and then tested 2 h later, the 
duration of the AITC-evoked nocifensive behaviors was significantly enhanced 




Figure 2-1. A single administration of oxaliplatin, but not cisplatin and paclitaxel, enhances 
AITC-evoked nocifensive behaviors. (A) Two hours after a single administration of vehicle or 
oxaliplatin (1, 5 or 10 mg/kg), mice received an intraplantar injection of vehicle (n = 3) or AITC (0.1%, 
20 µl; n = 7-14). (B) 1, 3 or 7 days after a single administration of vehicle or oxaliplatin (5 mg/kg), mice 
received an intraplantar injection of AITC (0.1%, 20 µl). n = 5-6. (C) Two hours after a single 
administration of vehicle or oxaliplatin (5 mg/kg), mice received an intraplantar injection of vehicle or 
menthol (1.6 µg, 20 µl). n = 6. (D) TRPA1+/+ or TRPA1−/− mice were intraperitoneally administered 
vehicle or oxaliplatin (5 mg/kg) 2 h before the menthol-evoked nocifensive behaviors. n = 3-4. (E) Two 
hours after a single administration of vehicle or oxaliplatin (5 mg/kg), mice received an intraplantar 
injection of vehicle or capsaicin (160 µg, 20 µl). n = 6. (F-G) Two hours after a single administration of 
oxalate (1.7 mg/kg; F), cisplatin (5 mg/kg; G), paclitaxel (6 mg/kg; H) or vehicle, mice received an 
intraplantar injection of AITC (0.1%, 20 µl). n = 6-7. AITC- and capsaicin-evoked nocifensive behaviors 
were measured for 20 min and 5 min, respectively; menthol-evoked nocifensive-like behaviors were 
scored for 5 min. Data are presented as the means ± S.E.M. * p < 0.05; ** p < 0.01. 
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By contrast, a 2-h pre-injection of cisplatin (5 mg/kg, i.p.) or paclitaxel (6 mg/kg, i.p.) 
had no effects on the duration of the AITC-evoked nocifensive behaviors (Fig. 2-1G, 
H).  
Oxaliplatin enhances the response to TRPA1 agonist, but not that of 
TRPM8 and TRPV1 agonists, in cultured DRG neurons 
 The effects of oxaliplatin pretreatment on the responses to TRPA1, TRPM8, and 
TRPV1 agonists in cultured DRG neurons isolated from naïve mice were assessed by 
calcium imaging. An application of the TRPA1 agonist AITC at concentrations of 1, 10 
and 100 µM to naïve cultured DRG neurons concentration-dependently evoked a [Ca2+]i 
increase in approximately 5.0 ± 1.3%, 22.2 ± 3.2% and 38.2 ± 2.8% of the cells, 
respectively, consistent with previous reports (25-45%) [48-50]. To better detect 
alterations of TRPA1 function, cultured DRGs were treated with a relatively low AITC 
concentration of 10 µM. In cultured DRG neurons pretreated with oxaliplatin (30, 100 
and 300 µM) for 2 h, the numbers of 10 µM AITC-sensitive cells were increased in a 
concentration-dependent manner, although the amplitudes of increase in F340/F380 ratio 
seemed to be less or not increased (Fig. 2-2). I quantitatively assessed the numbers of 
AITC-sensitive cells. In cultured DRG neurons pretreated with oxaliplatin (30 µM) for 
1, 2 and 4 h, the numbers of AITC-sensitive cells were not changed, compared with 
those pretreated with vehicle for 1, 2 and 4 h (F1,30 = 2.55, P = 0.121) (Fig. 2-3A). By 
contrast, the numbers of AITC-sensitive cells pretreated with oxaliplatin (100 or 
300 µM) for 1, 2 and 4 h were significantly increased (F1,24 = 14,24, P < 0.001 and 
F1,30 = 18.85, P < 0.001, respectively). Although the changes became apparent at 1 h, 
significant differences reached at 2 and 4 h of oxaliplatin pretreatment (Fig. 2-3B, C). 
 An application of menthol (100 µM) evoked a [Ca2+]i increase in 4-6% of cultured 
DRG neurons pretreated with vehicle, which was consistent with (4.2-7% [51-53]) or 
less than previous reports (10-17% [44, 46, 49, 54, 55]). In cultured DRG neurons 
pretreated with oxaliplatin (100 µM) for 1, 2, or 4 h, there was no change in the number 
of menthol-sensitive cells at any time point (Fig. 2-3D). Similarly, an application of 
capsaicin at a relatively low concentration of 500 nM evoked a [Ca2+]i increase in 
22-29% of vehicle-treated cultured DRG neurons, with no change in the number of 





Figure 2-2. Oxaliplatin pretreatment increases the AITC-evoked Ca2+response in cultured DRG 
neurons. The cultured neurons were pretreated with vehicle (A) or oxaliplatin at concentrations of 30 
(B), 100 (C) or 300 µM (D) for 2 h after which AITC (10 µM) was added for 3 min. Representative image 
of fluorescence (upper panels) and Ca2+ concentration (F340/F380 ratio) recorded in individual cultured 
DRG neurons (lower panels). All neurons in the fields were identified based on the [Ca2+]i increase 
elicited by the application of 50 mM KCl. Cell numbers in (AITC-sensitive DRG neurons)/(Total counted 
neurons) in the representative data are indicated in parentheses in lower panels. 
 
 
Figure 2-3. Oxaliplatin pretreatment increases the number of AITC-sensitive DRG neurons. (A- 
C) In cultured DRG neurons pretreated with vehicle or oxaliplatin at concentrations of 30 (A), 100 ( B) 
or 300 µM (C) for 1, 2, or 4 h, AITC (10 µM) was added for 3 min. (D, E) In cultured DRG neurons 
pretreated with vehicle or oxaliplatin (100 µM) for 1, 2, or 4 h, menthol (100 µM; D) or capsaicin (500 
nM; E) was added for 3 min, and the Ca2+ responses of the neurons were determined. Cells were 
considered responsive if their F340/F380 ratio increased by more than 0.2 during the 3-min application. 
The values show the percentage of agonist-sensitive cells in 50 mM KCl-positive neurons. Data are 
presented as the mean ± S.E.M. of 4-6 separate experiments. *p < 0.05, compared with corresponding 
vehicle-pretreatment. 
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Involvement of TRPA1 in acute oxaliplatin-induced cold hypersensitivity 
 To determine whether TRPA1 is involved in acute oxaliplatin-induced cold 
hypersensitivity, I examined the effects of a TRPA1 antagonist and of TRPA1 
deficiency. In the cold plate test, escape behavior scores measured in response to cold 
stimulation were significantly higher in mice tested 2 h after oxaliplatin (5 mg/kg, i.p.) 
administration than in mice tested 2 h after vehicle administration. In 2-h 
vehicle-administered mice, an injection of the TRPA1 antagonist HC-030031 
(100 mg/kg, i.p.) 30 min before the cold plate test tended to decrease the cold escape 
behavior scores, although the effect was not significant. In 2-h oxaliplatin-administered 
mice, HC-030031 significantly inhibited oxaliplatin-induced acute cold hypersensitivity 
compared to 30-min vehicle-injected mice (Fig. 2-4A). Similarly, Trpa1+/+ mice 
exhibited acute cold hypersensitivity 2 h after oxaliplatin (5 mg/kg) administration, 







Figure 2-4. TRPA1 is involved in oxaliplatin-induced acute cold hypersensitivity. (A) Mice were 
intraperitoneally administered vehicle or oxaliplatin (5 mg/kg) 2 h before the cold plate test, with vehicle 
or HC-030031 (100 mg/kg) intraperitoneally injected 30 min before testing. n = 6. (B) TRPA1+/+ or 
TRPA1−/− mice were intraperitoneally administered vehicle or oxaliplatin (5 mg/kg) 2 h before the cold 
plate test. n = 7-8. Escape behaviors in response to cold stimulation (5°C) were scored in a cold plate 
test. Data are presented as the mean ± S.E.M. ** p < 0.01, *** p < 0.001. 
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Discussion 
 In the present study, I provide the first evidence that TRPA1 in DRG neurons mediates 
the acute phase of oxaliplatin-induced peripheral neuropathy, as supported by the 
following results. 1) A single administration of oxaliplatin, as well as its metabolite 
oxalate, produced rapid-onset cold hypersensitivity within 2 h; this response was 
blocked by a TRPA1 antagonist and by TRPA1 deficiency. 2) Nocifensive behaviors 
evoked by AITC and menthol, but not by capsaicin, were enhanced 2 h after oxaliplatin 
administration. 3) Pretreatment of the cultured DRG neurons with oxaliplatin for 2-4 h 
increased the number of AITC-, but not of menthol- and capsaicin-sensitive neurons. 
 The major finding of this study is that oxaliplatin leads to the selective enhancement of 
TRPA1-mediated responses within a relatively short time, both in vivo and in vitro. 
AITC-evoked nocifensive behaviors and Ca2+ influx in DRG neurons are mediated 
through the activation of TRPA1 [47, 48]. Oxaliplatin increased both of these 
TRPA1-mediated responses within several hours, suggesting that it rapidly leads to an 
enhanced TRPA1 responsiveness in sensory neurons. The finding that oxalate enhanced 
AITC-evoked nocifensive behaviors suggests that the rapid-onset effects characteristic 
of oxaliplatin are caused by its metabolite, oxalate, or by an oxalate-related structure of 
oxaliplatin. Consistent with my findings, Sakurai et al. showed that both oxaliplatin and 
oxalate induce an early-phase (several hours) cold hyperalgesia in the acetone test, 
whereas a late-phase mechanical allodynia is induced by oxaliplatin or its another 
metabolite dichloro(1,2-diaminocyclohexane)platinum, but not oxalate, in rats [13]. On 
the other hand, the oxaliplatin-induced enhancement of AITC-evoked nocifensive 
behaviors lasted, at least, 3 days after the administration, suggesting that the enhanced 
TRPA1 responsiveness contributes to not only the acute (several hours), but also, at 
least, subacute (several days) oxaliplatin-induced cold hypersensitivity. 
 Despite some controversies, recent evidence points to the involvement of TRPA1 in 
oxaliplatin-induced subacute and chronic peripheral neuropathy [14, 23, 24, 56]. As 
previous studies shown, subacute (several days) mechanical and cold 
hypersensitivities-induced by a single administration of oxaliplatin were inhibited by 
either a TRPA1 antagonist or TRPA1 deficiency [14, 23], while the antagonist failed to 
inhibit the oxaliplatin-enhanced cold-temperature avoidance behavior [14]. Furthermore, 
subacute (several days) and chronic (several weeks) administration of oxaliplatin 
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increases TRPA1 mRNA levels in DRGs and in the trigeminal ganglion [14, 24]. 
Controversially, a transient up-regulation of TRPA1 mRNA is observed in DRGs only 
6 h after a single administration of oxaliplatin [23]. However, it is unlikely that 
oxaliplatin is able to increase the expression of functional TRPA1 protein within several 
hours of its administration. In the Ca2+ imaging experiments of the present study, the 
AITC concentration was set relatively low (10 µM). Nonetheless, following oxaliplatin 
treatment, 10 µM AITC produced nearly the same proportion of sensitive neurons 
(approximately 40%) as obtained with the submaximal concentration of AITC 
(100 µM) used in the control. Therefore, it is likely that oxaliplatin acutely produces an 
enhanced TRPA1 responsiveness by increasing the sensitivity to AITC, i.e., through the 
sensitization of existing TRPA1 and not by an increase in the number of 
TRPA1-expressing cells. Under inflammatory conditions, TRPA1 sensitization involves 
its translocation to the plasma membrane via phospholipase C and protein kinase A 
(PKA) signaling [57, 58]. Acute oxaliplatin may likewise induce the TRPA1 
sensitization via PKA signaling [56] or through other mechanisms specific to 
oxaliplatin and oxalate. 
 TRPM8 is expressed in a subpopulation of small-diameter sensory neurons, which 
correlates with responses to cooling and menthol [45, 59, 60]. Menthol sensation is 
mainly ascribed to TRPM8, while it also activates TRPA1 in a bimodal manner [48]. In 
Ca2+ imaging experiments, menthol-sensitive DRG neurons are largely abolished in 
TRPM8−/− mice, although a small population of menthol-sensitive neurons remains, 
probably via TRPA1 activation [51, 61]. Nevertheless, I found no change in the number 
of menthol-sensitive DRG neurons in response to oxaliplatin, suggesting that it has no 
acute effect on TRPM8-mediated responses. Although menthol-sensitive DRG neurons 
mediated thorough TRPA1 activation might be increased by acute oxaliplatin, they may 
be undetectable probably due to too small population or weak activation of TRPA1 by 
100 µM menthol in a bimodal phase [48]. Supporting my findings, oxaliplatin enhances 
Ca2+ responses to icilin (TRPA1/TRPM8 agonist), but not WS12 (TRPM8 selective 
agonist), in rat DRG neurons [56]. By contrast, my present findings showed that 
menthol-evoked nocifensive-like behaviors were enhanced after acute oxaliplatin 
administration, which was inhibited by TRPA1 deficiency. Since it is possible that 
menthol-evoked nocifensive-like behaviors are mediated through TRPA1 activation 
[62], they may be increased by the enhanced responsiveness of TRPA1 after acute 
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oxaliplatin administration in the dose of menthol used in this study. Several studies 
examine the involvement of TRPM8 in oxaliplatin-induced peripheral neuropathy. The 
subacute, but not chronic, effects of oxaliplatin administration were shown to include a 
transient up-regulation of TRPM8 mRNA in DRGs [14, 24, 25]. In TRPM8−/− mice, 
oxaliplatin-enhanced cold avoidance is abolished, while there is no change in 
oxaliplatin-induced mechanical hypersensitivity [14]. Pharmacological blockade of 
TRPM8 has no effect on oxaliplatin-induced subacute cold hypersensitivity [46]. Thus, 
although TRPM8 involvement in oxaliplatin-induced subacute peripheral neuropathy 
remains to be clarified, my findings seem to rule out an important role for TRPM8 in 
oxaliplatin-induced acute peripheral neuropathy  
 A body of evidence suggests that TRPV1 plays a role in chemotherapy-induced 
chronic peripheral neuropathy [20, 21, 34], similar to the neuropathic pain induced by 
peripheral nerve injury [63]. However, in the present study, neither cisplatin nor 
paclitaxel altered capsaicin-evoked, TRPV1-mediated nocifensive behaviors. 
Furthermore, oxaliplatin had no rapid-onset effect on capsaicin-evoked nocifensive 
behaviors or the number of capsaicin-sensitive DRG neurons, suggesting that 
oxaliplatin-induced acute peripheral neuropathy is not mediated by TRPV1. Consistent 
with the present findings, other studies did not find evidence of TRPV1 involvement in 
oxaliplatin-induced subacute and chronic cold hypersensitivity [23-25].  
 Accumulating evidence suggests that oxaliplatin, as a platinum-based drug like 
cisplatin, induces chronic peripheral neuropathy by its direct and indirect neurotoxic 
effects on peripheral sensory neurons [5, 23]. The painful neurotoxicity may secondarily 
up-regulate and/or sensitize TRPA1, TRPV1, and TRPM8, as occurs in nerve 
injury-induced neuropathic pain [63-65]. However, our results indicate that oxaliplatin 
leads to a rapid, preferentially enhanced responsiveness of TRPA1. Since the rapid 
effect of the drug is unlikely to be due to its neurotoxicity on sensory neurons, a more 
likely explanation is an alteration in TRPA1 function, either directly or indirectly, 
within several hours, although the mechanisms remain unclear.  
 Taken together, these results suggest that a brief treatment with oxaliplatin or its 
metabolite oxalate is sufficient to enhance the responsiveness of TRPA1 but not that of 
TRPM8 and TRPV1 expressed by DRG neurons, which may contribute to the 





Figure 2-5. Schematic diagram depicting the involvements of thermal TRP channel in 
oxaliplatin-induced acute cold hypersensitivity 
A brief treatment with oxaliplatin or its metabolite oxalate is sufficient to enhance the responsiveness of 
TRPA1 but not that of TRPM8 and TRPV1 expressed by DRG neurons, which may contribute to the 






Chapter 3 Mechanisms of TRPA1 activation in 
oxaliplatin-induced acute cold hypersensitivity  
Oxaliplatin, a platinum-based chemotherapeutic agent, causes peculiar acute 
peripheral neuropathy. Oxaliplatin-induced acute peripheral neuropathy appears in 
almost all patients rapidly after infusion and is triggered or exacerbated by cold, but the 
mechanisms are poorly understood. I hypothesized that TRPA1, a cation channel 
activated by oxidative stress and cold temperature, contributes to acute cold 
hypersensitivity induced by oxaliplatin. Recently, I have established a mouse model of 
rapid-onset cold hypersensitivity induced by oxaliplatin and reported that acute cold 
hypersensitivity induced by oxaliplatin is caused by the enhanced responsiveness of 
TRPA1 in mice. In this study, I further explored the mechanisms how TRPA1 is 
activated and/or sensitized by oxaliplatin. 
In Ca2+ imaging and patch-clamp using HEK293 cells expressing human TRPA1, 
high concentrations of oxaliplatin (100-1000 µM) evoked Ca2+ response and increased 
whole-cell currents, respectively, but not in mock-transfected cells. The 
oxaliplatin-induced Ca2+ response was abolished by a TRPA1 antagonist, HC-030031, 
an antioxidant, glutathione and a reactive oxygen species (ROS) scavenger, PBN. To 
determine the site of action to oxaliplatin on TRPA1, I used several mutated TRPA1 
mutating cysteine residues to serine and examined the responsiveness of these mutant 
clones in oxaliplatin-induced TRPA1 activation by Ca2+ imaging test. I found that 
oxaliplatin activated TRPA1 through oxidative cysteine modification, which perhaps 
mediated by hydrogen peroxide (H2O2). Moreover, in HEK293 cells preloaded with 
H2O2-specific indicator PG1, I confirmed that oxaliplatin increased H2O2 production. 
These data suggest that high concentration of oxaliplatin-induced TRPA1 activation is 
mediated through ROS production.  
However, the concentration of oxaliplatin used in whole cell pacth clamp method 
and Ca2+ imaging test was 1 mM, which is higher than blood concentration of 
oxaliplatin. Thus, I supposed there might be other mechanisms of oxaliplatin to 
sensitize but not activate TRPA1. Next, I investigated the effects of a relatively lower 
concentration of oxaliplatin pretreatment on H2O2-evoked TRPA1 responses. In 
TRPA1-expressed HEK293 cells, pretreatment with 100 µM oxaliplatin for 2 h 
increased H2O2 (10 µM)-evoked Ca2+ response. In cell-attached patches, number of 
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open channels x open probability (NPo) of TRPA1 channel was significantly increased 
after oxaliplatin pretreatment. Finally, when mice were treated with oxaliplatin (5 
mg/kg) for 2 h, nocifensive behaviors evoked by intraplantar injection of H2O2 (0.5%, 
20 µl) were significantly enhanced. 
 What is the mechanism of oxaliplatin-induced TRPA1 sensitization? Although some 
studies show TRPA1 mRNA is increased in DRGs after oxaliplatin administration, it is 
unlikely that oxaliplatin is able to increase the expression of functional TRPA1 protein 
within several hours of its administration. Interestingly, some group demonstrates 
TRPA1 membrane levels are increased by AITC stimuli, suggesting TRPA1 
translocation to the membrane might represent one of the mechanisms controlling 
TRPA1 functionality upon acute activation. Therefore, I also investigated the whether 
TRPA1 membrane levels would change after oxalipaltin treatment in 
TRPA1-transfected HEK293 cells (data not shown). However, TRPA1 membrane levels 
were not changed after oxaliplatin pretreated for several hours, compared to 
vehicle-pretreated group. Thus, I considered that the increase of total TRPA1 protein 
expression or TRPA1 membrane levels have little effect on oxaliplatin-induced TRPA1 
sensitization.  
 The present study reveals mechanisms of TRPA1 in oxaliplatin-induced acute cold 
hypersensitivity, as supported by the following results. 1) TRPA1 is activated by high 
concentration oxaliplatin; this response was inhibited by cysteine residues mutations 
and also by antioxidant or ROS scavenger. 2) On the other hand, low concentration 
oxaliplatin sensitize TRPA1 to ROS; which was proved by pretreatment of low 
concentration oxalipaltin enhanced the H2O2-evoked TRPA1 responses in vivo and in 
vitro. 
 Taken together, these results suggest oxaliplatin could sensitize TRPA1 function, and 
subsequently the sensitized TRPA1 is activated by ROS probably produced from 
platinum-based chemotherapeutic agent-mediated mitochondrial dysfunction, which 





 In this study, I explored the mechanisms of oxaliplatin-induced acute peripheral 
neuropathy as follows: 
 In chapter 1, I established a new oxaliplatin-induced acute cold hypersensitivity 
mouse model. A single intraperitoneal administration of oxaliplatin induced a 
characteristic acute cold hypersensitivity, while mechanical hypersensitivity was not 
observed, which is similar with the clinical observation. Then the effects of standard 
analgesics on the oxaliplatin-induced cold hypersensitivity were evaluated in this mouse 
model. I found that gabapentin, mexiletine, tramadol and calcium gluconate 
significantly inhibited, and morphine and milnacipran decreased the acute cold 
hypersensitivity, while diclofenac and amitriptyline had no effects. These results 
suggest that gabapentin, mexiletine and calcium gluconate are effective against 
oxaliplatin-induced acute peripheral neuropathy. 
 In chapter 2, the involvements of thermosensitive TRP channels were evaluated. 
Pre-treatment of oxalipaltin enhanced TRPA1 channel agonist-evoked nocifensive 
behaviors and [Ca2+]i responses in cultured DRG neurons, respectively. Moreover, the 
oxaliplatin-induced cold hypersensitivity was inhibited by TRPA1 knockout mice and a 
TRPA1 antagonist, HC030031. The present data suggest that the acute cold 
hypersensitivity characteristically induced by oxaliplatin could be linked to an enhanced 
responsiveness of TRPA1, but not TRPM8 and TRPV1, on DRG neurons.  
 In chapter 3, the mechanisms of TRPA1 activation/sensitization were further 
investigated. High concentration of oxaliplatin elicited TRPA1 activation directly, while 
low concentration of oxaliplatin pretreatment enhanced hydrogen peroxide-evoked 
responses. Taken together, these results suggest oxaliplatin could sensitize TRPA1 
function, and subsequently the sensitized TRPA1 is activated by ROS probably 
produced from oxaliplatin-mediated mitochondrial dysfunction, which may contribute 
to the oxaliplatin-induced acute peripheral neuropathy. 
 In conclusion, present study highlights TRPA1 plays a critical role in 
oxaliplatin-induced acute cold hypersensitivity and TRPA1 antagonists as a promising 
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